1
|
Pusztai L, Denkert C, O'Shaughnessy J, Cortes J, Dent R, McArthur H, Kümmel S, Bergh J, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Zhu Y, Pan W, Tryfonidis K, Schmid P. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522. Ann Oncol 2024; 35:429-436. [PMID: 38369015 DOI: 10.1016/j.annonc.2024.02.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2023] [Revised: 02/05/2024] [Accepted: 02/08/2024] [Indexed: 02/20/2024] Open
Abstract
BACKGROUND KEYNOTE-522 demonstrated statistically significant improvements in pathological complete response (pCR) with neoadjuvant pembrolizumab plus chemotherapy and event-free survival (EFS) with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab in patients with high-risk, early-stage triple-negative breast cancer (TNBC). Prior studies have shown the prognostic value of the residual cancer burden (RCB) index to quantify the extent of residual disease after neoadjuvant chemotherapy. In this preplanned exploratory analysis, we assessed RCB distribution and EFS within RCB categories by treatment group. PATIENTS AND METHODS A total of 1174 patients with stage T1c/N1-2 or T2-4/N0-2 TNBC were randomized 2 : 1 to pembrolizumab 200 mg or placebo every 3 weeks given with four cycles of paclitaxel + carboplatin, followed by four cycles of doxorubicin or epirubicin + cyclophosphamide. After surgery, patients received pembrolizumab or placebo for nine cycles or until recurrence or unacceptable toxicity. Primary endpoints are pCR and EFS. RCB is a prespecified exploratory endpoint. The association between EFS and RCB was assessed using a Cox regression model. RESULTS Pembrolizumab shifted patients into lower RCB categories across the entire spectrum compared with placebo. There were more patients in the pembrolizumab group with RCB-0 (pCR), and fewer patients in the pembrolizumab group with RCB-1, RCB-2, and RCB-3. The corresponding hazard ratios (95% confidence intervals) for EFS were 0.70 (0.38-1.31), 0.92 (0.39-2.20), 0.52 (0.32-0.82), and 1.24 (0.69-2.23). The most common first EFS events were distant recurrences, with fewer in the pembrolizumab group across all RCB categories. Among patients with RCB-0/1, more than half [21/38 (55.3%)] of all events were central nervous system recurrences, with 13/22 (59.1%) in the pembrolizumab group and 8/16 (50.0%) in the placebo group. CONCLUSIONS Addition of pembrolizumab to chemotherapy resulted in fewer EFS events in the RCB-0, RCB-1, and RCB-2 categories, with the greatest benefit in RCB-2. These findings demonstrate that pembrolizumab not only increased pCR rates, but also improved EFS among most patients who do not have a pCR.
Collapse
MESH Headings
- Humans
- Female
- Antibodies, Monoclonal, Humanized/therapeutic use
- Antibodies, Monoclonal, Humanized/administration & dosage
- Antibodies, Monoclonal, Humanized/adverse effects
- Triple Negative Breast Neoplasms/drug therapy
- Triple Negative Breast Neoplasms/pathology
- Triple Negative Breast Neoplasms/mortality
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Neoplasm, Residual/pathology
- Middle Aged
- Paclitaxel/administration & dosage
- Paclitaxel/therapeutic use
- Paclitaxel/adverse effects
- Carboplatin/administration & dosage
- Neoadjuvant Therapy/methods
- Neoplasm Staging
- Cyclophosphamide/administration & dosage
- Cyclophosphamide/therapeutic use
- Cyclophosphamide/adverse effects
- Aged
- Adult
- Doxorubicin/therapeutic use
- Doxorubicin/administration & dosage
- Epirubicin/administration & dosage
- Epirubicin/therapeutic use
- Progression-Free Survival
- Chemotherapy, Adjuvant/methods
- Antineoplastic Agents, Immunological/therapeutic use
- Antineoplastic Agents, Immunological/adverse effects
- Antineoplastic Agents, Immunological/administration & dosage
- Double-Blind Method
Collapse
Affiliation(s)
- L Pusztai
- Yale School of Medicine, Yale Cancer Center, New Haven, USA.
| | - C Denkert
- Institute of Pathology, Philipps-University Marburg and University Hospital Marburg, Marburg, Germany
| | - J O'Shaughnessy
- Baylor University Medical Center, Texas Oncology, US Oncology Network, Dallas, USA
| | - J Cortes
- International Breast Cancer Center, Quironsalud Group, Barcelona; Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain
| | - R Dent
- National Cancer Center Singapore, Duke - National University of Singapore Medical School, Singapore, Singapore
| | - H McArthur
- University of Texas Southwestern Medical Center, Dallas, USA
| | - S Kümmel
- Breast Unit, Kliniken Essen-Mitte, Essen; Charité - Universitätsmedizin Berlin, Department of Gynecology with Breast Center, Berlin, Germany
| | - J Bergh
- Department of Oncology-Pathology, Karolinska Institutet and Breast Cancer Centre, Cancer Theme, Karolinska University Hospital, Karolinska Comprehensive Cancer Center, Solna, Sweden
| | - Y H Park
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - R Hui
- Westmead Breast Cancer Institute, Westmead Hospital and the University of Sydney, Sydney, Australia
| | - N Harbeck
- Breast Center, Department of Obstetrics and Gynaecology, LMU University Hospital, Munich, Germany
| | - M Takahashi
- Hokkaido University Hospital, Sapporo, Japan
| | - M Untch
- Breast Cancer Center, Helios Klinikum Berlin-Buch, Berlin
| | - P A Fasching
- University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
| | - F Cardoso
- Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
| | - Y Zhu
- Oncology, Merck & Co., Inc., Rahway, USA
| | - W Pan
- Oncology, Merck & Co., Inc., Rahway, USA
| | | | - P Schmid
- Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK
| |
Collapse
|
2
|
Zhang JN, Hui R. [Injury mechanism, clinical status and prospects of traumatic brain injury]. Zhonghua Yi Xue Za Zhi 2024; 104:985-990. [PMID: 38561293 DOI: 10.3760/cma.j.cn112137-20231012-00724] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 04/04/2024]
Abstract
Traumatic brain injury (TBI) is an important in the world's public health and an important subject of basic and clinical research in the medical field. In the past 30 years, the epidemiology, injury mechanism, safety prevention, medical strategies, nursing measures and other aspects of TBI have made great progress, and the level of treatment has also been continuously improved, but it still faces many challenges. The focus of research on the injury mechanism of TBI has gradually shifted from the classic signaling pathways of primary injury to the study of secondary injury mechanisms. Pharmacological research on various therapeutic targets has also made significant progress, which is expected to be transformed into new TBI therapeutic drugs. On the other hand, many new clinical concepts, new systems, and new methods are constantly being integrated into the diagnosis and treatment of TBI, which has gradually transformed from the original treatment of acute neurological injury to the comprehensive treatment of chronic systemic diseases. This paper is based on the latest research progress in the basic and clinical aspects of TBI, and provides a review of its current status and development trends, providing reference for the medical treatment and research of TBI.
Collapse
Affiliation(s)
- J N Zhang
- Department of Neurosurgery, General Hospital of the People's Liberation Army, Beijing 100853,China
| | - R Hui
- Department of Neurosurgery, General Hospital of the People's Liberation Army, Beijing 100853,China
| |
Collapse
|
3
|
Kümmel S, Schmid P, Harbeck N, Takahashi M, Untch M, Boileau JF, Cortes J, McArthur H, Dent R, O’Shaughnessy J, Pusztai L, Foukakis T, Park Y, Hui R, Cardoso F, Denkert C, Zhu Y, Pan W, Karantza V, Fasching P. P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study. Breast 2023. [DOI: 10.1016/s0960-9776(23)00242-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/15/2023] Open
|
4
|
Hamilton E, Meisel J, Alemany C, Virginia B, Lin N, Wesolowski R, Mathauda-Sahota G, Makower D, Lawrence J, Faltaos D, Mitri Z, Sabanathan D, Clark D, Pluard T, Hui R, McCarthy N, Patel M. Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826). Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00896-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
5
|
Abstract
To study the changes of plantar fascia in patients with knee osteoarthritis. Collect knee arthritis surgery patients and according to the length of the course is divided into long-course and short-course group, collection of healthy volunteers as control group at the same time, basic information such as age, height, weight, and body mass index (BMI) were recorded; the application of Philips and Siemens ultrasonic diagnostic instrument, a foot plantar fascia in patients with knee osteoarthritis in ultrasonic scanning, measuring the thickness of the heel of plantar fascia, observe its sonographic manifestation; age, BMI, and plantar fascia thickness were compared between groups. The plantar fascia thickness of the normal control group was 0.30 ± 0.06 cm on the left side and 0.30 ± 0.05 cm on the right side. The plantar fascia thickness of the long-course group was 0.44 ± 0.10 cm on the left side and 0.42 ± 0.10 cm on the right side. The plantar fascia thickness of the group with short course of disease was 0.37 ± 0.06 cm on the left side and 0.34 ± 0.7 cm on the right side. Multivariable analysis of variance was used to compare the thickness of plantar fascia in the long-course group, the short-course group, and the control group, P < .05; there were statistical differences among the 3 groups. Multivariate analysis of variance was used to compare the general data of the long-course group, the short-course group, and the control group. Age: the long-course group was compared with the short-course group and the control group, P < .05; short-course group compared with control group, P > .05. BMI: compared with long-course group and short-course group, P < .05; long course of disease group compared with short course of disease group, P > .05. BMI was statistically different between the case group and the control group. Plantar fascia was thickened in patients with knee osteoarthritis, and the thickening of plantar fascia was related to BMI. The thickening of plantar fascia was uneven, and the degree of thickening was related to the course of disease. At the same time, the sonogram of plantar fascia was less echogenic than that of normal controls.
Collapse
Affiliation(s)
- Zongjie Liu
- Department of Ultrasound Medicine, The Thrid Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, People’s Republic of China
| | - Xin Sui
- Department of Ultrasound Medicine, The Thrid Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, People’s Republic of China
- *Correspondence: Sui Xin, Department of Ultrasound Medicine, The Third Hospital of Hebei Medical University, No. 139, Ziqiang Road, Shijiazhuang 050051, Hebei Province, China (e-mail: )
| | - Ran Hui
- Department of Ultrasound Medicine, The Thrid Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, People’s Republic of China
| | - Ying Zhao
- Department of Ultrasound Medicine, The Thrid Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, People’s Republic of China
| | - Hua Li
- Department of Ultrasound Medicine, The Thrid Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, People’s Republic of China
| | - Xiaodan Huang
- Department of Orthopectics, The Thrid Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, People’s Republic of China
| |
Collapse
|
6
|
Rodriguez-Abreu D, Wu YL, Boyer M, Garassino M, Mok T, Cheng Y, Hui R, Kowalski D, Robinson A, Brahmer J, Leal T, Lopes G, Cho B, Nogami N, Novello S, Peled N, de Castro G, Leiby M, Chirovsky D, Lin J, Pietanza M, Reck M. OA15.06 Pooled Analysis of Outcomes with Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
7
|
Garassino M, Gadgeel S, Speranza G, Felip E, Esteban Gonzalez E, Domine Gomez M, Hochmair M, Powell S, Bischoff H, Peled N, Grossi F, Jennens R, Reck M, Hui R, Garon E, Kurata T, Gray J, Schwarzenberger P, Jensen E, Rodriguez Abreu D. 973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
8
|
Senan S, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Murakami S, Hui R, Faivre-Finn C, Paz-Ares L, Wu YL, Mann H, Dennis PA, Antonia SJ. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial. ESMO Open 2022; 7:100410. [PMID: 35247871 PMCID: PMC9058904 DOI: 10.1016/j.esmoop.2022.100410] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2021] [Revised: 01/11/2022] [Accepted: 01/22/2022] [Indexed: 12/25/2022] Open
Abstract
Background The phase III PACIFIC trial (NCT02125461) established consolidation durvalumab as standard of care for patients with unresectable, stage III non-small-cell lung cancer (NSCLC) and no disease progression following chemoradiotherapy (CRT). In some cases, patients with stage IIIA-N2 NSCLC are considered operable, but the relative benefit of surgery is unclear. We report a post hoc, exploratory analysis of clinical outcomes in the PACIFIC trial, in patients with or without stage IIIA-N2 NSCLC. Materials and methods Patients with unresectable, stage III NSCLC and no disease progression after ≥2 cycles of platinum-based, concurrent CRT were randomized 2 : 1 to receive durvalumab (10 mg/kg intravenously; once every 2 weeks for up to 12 months) or placebo, 1-42 days after CRT. The primary endpoints were progression-free survival (PFS; assessed by blinded independent central review according to RECIST version 1.1) and overall survival (OS). Treatment effects within subgroups were estimated by hazard ratios (HRs) from unstratified Cox proportional hazards models. Results Of 713 randomized patients, 287 (40%) had stage IIIA-N2 disease. Baseline characteristics were similar between patients with and without stage IIIA-N2 NSCLC. With a median follow-up of 14.5 months (range: 0.2-29.9 months), PFS was improved with durvalumab versus placebo in both patients with [HR = 0.46; 95% confidence interval (CI), 0.33-0.65] and without (HR = 0.62; 95% CI 0.48-0.80) stage IIIA-N2 disease. Similarly, with a median follow-up of 25.2 months (range: 0.2-43.1 months), OS was improved with durvalumab versus placebo in patients with (HR = 0.56; 95% CI 0.39-0.79) or without (HR = 0.78; 95% CI 0.57-1.06) stage IIIA-N2 disease. Durvalumab had a manageable safety profile irrespective of stage IIIA-N2 status. Conclusions Consistent with the intent-to-treat population, treatment benefits with durvalumab were confirmed in patients with stage IIIA-N2, unresectable NSCLC. Prospective studies are needed to determine the optimal treatment approach for patients who are deemed operable. The PACIFIC trial established durvalumab after CRT as standard of care for unresectable, stage III NSCLC. The optimum multimodal treatment strategy for patients with potentially resectable, stage IIIA-N2 NSCLC is unknown. Survival benefit with durvalumab was observed in patients with stage IIIA-N2, unresectable NSCLC in this post hoc analysis. Durvalumab after CRT also exhibited a manageable safety profile in this subpopulation from PACIFIC. Studies of surgical vs. non-surgical strategies are needed to establish the best approach for potentially operable patients.
Collapse
Affiliation(s)
- S Senan
- Department of Radiation Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.
| | - M Özgüroğlu
- Istanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, Turkey
| | - D Daniel
- Tennessee Oncology, Chattanooga, USA; Sarah Cannon Research Institute, Nashville, USA
| | - A Villegas
- Cancer Specialists of North Florida, Jacksonville, USA
| | - D Vicente
- Hospital Universitario Virgen Macarena, Seville, Spain
| | | | - R Hui
- Westmead Hospital and the University of Sydney, Sydney, Australia
| | - C Faivre-Finn
- The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK
| | - L Paz-Ares
- Universidad Complutense, CiberOnc, CNIO and Hospital Universitario 12 de Octubre, Madrid, Spain
| | - Y L Wu
- Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
| | - H Mann
- AstraZeneca, Cambridge, UK
| | | | - S J Antonia
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
| |
Collapse
|
9
|
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park Y, Hui R, Harbeck N, Takahashi M, Untch M, Fasching P, Cardoso F, Ding Y, Tryfonidis K, Aktan G, Karantza V, O’Shaughnessy J. VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.06.014] [Citation(s) in RCA: 70] [Impact Index Per Article: 23.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
|
10
|
Griesinger F, Choi YL, Chou TY, Gregg J, Hui R, Leighl N, Marchetti A, Navani N, Bailey T, Silvey M, Makin R, Kahangire D, Chau M, Taylor A, Subramanian J. 144P Delays in epidermal growth factor receptor mutation (EGFRm) testing in advanced (stage IIIb/ IIIc/ IV) non-small cell lung cancer (NSCLC) patients and their impact on the use of first line tyrosine kinase inhibitor (TKIs) in a real-world setting. J Thorac Oncol 2021. [DOI: 10.1016/s1556-0864(21)01986-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
11
|
Subramanian J, Choi YL, Chou TY, Gregg J, Hui R, Leighl N, Marchetti A, Navani N, Bailey T, Silvey M, Makin R, Kahangire D, Chau M, Taylor A, Griesinger F. 135P The real-world use of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor mutated (EGFRm) advanced (stage IIIb/IIIc/IV) non-small cell lung cancer (NSCLC) patients. J Thorac Oncol 2021. [DOI: 10.1016/s1556-0864(21)01977-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
12
|
Hui R, Li Z, Liu Z, Liu X, Deng H. The clinical value of color Doppler ultrasonography in measuring the hemodynamics of liver cirrhosis patients' portal and splenic veins. Am J Transl Res 2021; 13:1692-1700. [PMID: 33841691 PMCID: PMC8014353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Accepted: 11/17/2020] [Indexed: 06/12/2023]
Abstract
OBJECTIVE To investigate the clinical value of color Doppler ultrasonography (CDUS) in measuring the hemodynamics of liver cirrhosis (LC) patients' portal and splenic veins. METHODS The clinical data of 81 LC patients admitted to our hospital were collected retrospectively and classified into Group A, and the clinical data from 51 healthy volunteers were classified into Group B. All the patients were examined with CDUS, and the ultrasonography images were analyzed. The hemodynamic indices of the portal and splenic veins were compared, and the differences in the hemodynamic indices of the LC patients with varying degrees of esophageal varices and hepatic injuries were analyzed. RESULTS Group A exhibited higher Qpv, Dpv, Qsv, and Dsv and lower Vpv and Vsv than Group B (P < 0.05). The Qpv and Dpv of the patients with Grade B LC were higher than they were in the patients with Grade A LC and lower than they were in the patients with Grade C LC (P < 0.05). The Vpv of the patients with Grade B LC was higher than it was in the patients with Grade C LC and lower than it was in the patients with Grade A LC (P < 0.05). The Qsv and Dsv of the patients with Grade B LC were higher than they were in the patients with Grade A LC and lower than they were in the patients with Grade C LC (P < 0.05). The Vsv of the patients with Grade B LC was higher than it was in the patients with Grade C LC and lower than it was in the patients with Grade A LC (P < 0.05). The patients with mild, moderate, and severe esophageal varices showed lower Vpv and Vsv and higher Qpv, Dpv, Qsv, and Dsv than the patients without esophageal varices (P < 0.05). CONCLUSION CDUS has certain clinical values in measuring the hemodynamics of LC patients' portal and splenic veins and can be used to predict the degrees of hepatic injuries and esophageal varices.
Collapse
Affiliation(s)
- Ran Hui
- Department of Ultrasound Medicine, The Third Hospital of Hebei Medical UniversityShijiazhuang 050051, Hebei Province, China
| | - Zhe Li
- Department of Ultrasound Medicine, The Third Hospital of Hebei Medical UniversityShijiazhuang 050051, Hebei Province, China
| | - Zongjie Liu
- Department of Ultrasound Medicine, The Third Hospital of Hebei Medical UniversityShijiazhuang 050051, Hebei Province, China
| | - Xiuping Liu
- Department of Obstetrics and Gynecology, The Third Hospital of Hebei Medical UniversityShijiazhuang 050051, Hebei Province, China
| | - Heping Deng
- Department of Ultrasound Medicine, The Third Hospital of Hebei Medical UniversityShijiazhuang 050051, Hebei Province, China
| |
Collapse
|
13
|
Liu J, Itchins M, Nagrial A, Cooper W, De Silva M, Barnet M, Varikatt W, Sivasubramaniam V, Davis A, Gill A, Blinman P, Lee K, Hui R, Gao B, Pavlakis N, Clarke S, Lee J, Boyer M, Kao S. P76.08 High Tumour PD-L1 Is Associated With Poor Outcomes in EGFR-Mutant Lung Cancer Treated With First Generation EGFR TKIs. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.1065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
14
|
Gray J, Rodríguez-Abreu D, Powell S, Hochmair M, Gadgeel S, Esteban E, Felip E, Speranza G, De Angelis F, Dómine M, Cheng S, Bischoff H, Peled N, Reck M, Hui R, Garon E, Boyer M, Kurata T, Yang J, Jensen E, Souza F, Garassino M. FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.141] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
15
|
Emerson P, Stefani L, Terluk A, Boyd A, Hui R, Thomas L. Left Atrial Strain Analysis in Breast Cancer Patients Post Anthracycline (AC). Heart Lung Circ 2021. [DOI: 10.1016/j.hlc.2021.06.225] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
16
|
Dent R, Cortes J, Pusztai L, McArthur H, Kuemmel S, Bergh J, Denkert C, Park Y, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching P, Cardoso F, Jia L, Jensen E, Karantza V, Aktan G, O'Shaughnessy J, Schmid P. 1O KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
17
|
Abstract
Objective: To explore the application of deep convolutional neural network theory in thyroid ultrasound image system analysis and eigenvalue extraction to help medically predict the patient’s condition. Methods: The thyroid color ultrasound image dataset of our hospital
was selected as the training and test samples. The comparison experiment was designed in the deep convolutional neural network learning framework to test the feasibility of the method. Results: Image information classification based on deep neural network algorithm can predict thyroid
nodule lesions well, and has good accuracy in the classification test of benign and malignant nodules. Conclusion: The clinical application of deep learning method and thyroid ultrasound image feature value extraction and system analysis can improve the accuracy of clinical thyroid
benign and malignant classification.
Collapse
Affiliation(s)
- Ran Hui
- The Third Hospital of Hebei Medical University, 050051, China
| | | | - Yu Liu
- The Fourth Hospital of Hebei Medical University, 050051, China
| | - Lin Shi
- The First Hospital of Shijiazhuang, 050011, China
| | - Chao Fu
- Hebei Normal University, 050024, China
| | - Ostfeld Ishsay
- Department of IT, College of Engineering and Technology, Dindigul 629702, Tamil Nadu, India
| |
Collapse
|
18
|
Su M, Wang J, Wang C, Wang X, Dong W, Qiu W, Wang Y, Zhao X, Zou Y, Song L, Zhang L, Hui R. Correction: MicroRNA-221 inhibits autophagy and promotes heart failure by modulating the p27/CDK2/mTOR axis. Cell Death Differ 2020; 28:420-422. [PMID: 32632292 DOI: 10.1038/s41418-020-0582-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- M Su
- State Key Laboratory of Cardiovascular Disease, Sino-German Laboratory for Molecular Medicine, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China
| | - J Wang
- State Key Laboratory of Cardiovascular Disease, Sino-German Laboratory for Molecular Medicine, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China
| | - C Wang
- State Key Laboratory of Cardiovascular Disease, Sino-German Laboratory for Molecular Medicine, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China
| | - X Wang
- State Key Laboratory of Cardiovascular Disease, Sino-German Laboratory for Molecular Medicine, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China
| | - W Dong
- Key Laboratory of Human Diseases Comparative Medicine, Ministry of Health, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
| | - W Qiu
- Department of Urology, Peking University First Hospital and the Institute of Urology, Beijing, 100034, China
| | - Y Wang
- State Key Laboratory of Cardiovascular Disease, Sino-German Laboratory for Molecular Medicine, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China
| | - X Zhao
- Department of Cardiology, Qingdao Municipal Hospital, Qingdao University, Qingdao, 266071, China
| | - Y Zou
- State Key Laboratory of Cardiovascular Disease, Sino-German Laboratory for Molecular Medicine, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China
| | - L Song
- State Key Laboratory of Cardiovascular Disease, Sino-German Laboratory for Molecular Medicine, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China
| | - L Zhang
- Key Laboratory of Human Diseases Comparative Medicine, Ministry of Health, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
| | - R Hui
- State Key Laboratory of Cardiovascular Disease, Sino-German Laboratory for Molecular Medicine, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China.
| |
Collapse
|
19
|
Escriva-Bou A, Hui R, Maples S, Medellín-Azuara J, Harter T, Lund JR. Planning for groundwater sustainability accounting for uncertainty and costs: An application to California's Central Valley. J Environ Manage 2020; 264:110426. [PMID: 32217315 DOI: 10.1016/j.jenvman.2020.110426] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/13/2019] [Revised: 02/14/2020] [Accepted: 03/09/2020] [Indexed: 06/10/2023]
Abstract
In regions experiencing aquifer depletion, planning for groundwater sustainability requires both accurate accounting of current groundwater budgets and an assessment of future conditions, with changes in recharge and pumping. Hydrologic variability, climate change effects on water flows, changing water infrastructure operations, and inherent uncertainties in modeling, challenge the plans to achieve groundwater sustainability. This paper examines the importance, magnitude, and policy implications of uncertainties in groundwater overdraft estimation for water management in California. We review water balance estimates from two regional-scale groundwater models-C2VSim and CVHM-for sub-regions within California's Central Valley, and examine the variability and uncertainty in historical and future estimates of groundwater overdraft. Assuming reductions in agricultural water use for sub-regions with overdraft, we estimate the probabilities of ending groundwater overdraft for different periods. We also obtain the economic costs associated with these reductions in agricultural production. Results from both groundwater models show significant inter-annual variability in flows affecting groundwater storage, and our model comparison highlights the uncertainty in water budget estimates for Central Valley sub-regions given the differences between models. The analysis of the probabilities of achieving sustainability at the sub-regional scale show that the average overdraft rate is important and that greater variance in annual groundwater storage increases uncertainties in ending overdraft, especially for shorter periods. Greater reductions in annual net water increases the reliability of achieving groundwater sustainability, but rising rapidly agricultural economic losses. Setting management thresholds below groundwater levels can ease meeting sustainability criteria, but also can introduce a false pathway to sustainability. Finally, we discuss policy implications for the design of local groundwater sustainability plans and state assessment and regulation of local plans.
Collapse
Affiliation(s)
- A Escriva-Bou
- Water Policy Center, Public Policy Institute of California, California, USA.
| | - R Hui
- Center for Watershed Sciences, University of California, Davis, CA, USA
| | - S Maples
- Department of Land, Air, and Water Resources, University of California, Davis, CA, USA
| | - J Medellín-Azuara
- Department of Civil and Environmental Engineering, University of California, Merced, CA, USA
| | - T Harter
- Center for Watershed Sciences, University of California, Davis, CA, USA; Department of Land, Air, and Water Resources, University of California, Davis, CA, USA
| | - J R Lund
- Center for Watershed Sciences, University of California, Davis, CA, USA
| |
Collapse
|
20
|
Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortés J. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Ann Oncol 2020; 30:397-404. [PMID: 30475950 DOI: 10.1093/annonc/mdy517] [Citation(s) in RCA: 494] [Impact Index Per Article: 123.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Treatment options for previously treated metastatic triple-negative breast cancer (mTNBC) are limited. In cohort A of the phase II KEYNOTE-086 study, we evaluated pembrolizumab as second or later line of treatment for patients with mTNBC. PATIENTS AND METHODS Eligible patients had centrally confirmed mTNBC, ≥1 systemic therapy for metastatic disease, prior treatment with anthracycline and taxane in any disease setting, and progression on or after the most recent therapy. Patients received pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years. Primary end points were objective response rate in the total and PD-L1-positive populations, and safety. Secondary end points included duration of response, disease control rate (percentage of patients with complete or partial response or stable disease for ≥24 weeks), progression-free survival, and overall survival. RESULTS All enrolled patients (N = 170) were women, 61.8% had PD-L1-positive tumors, and 43.5% had received ≥3 previous lines of therapy for metastatic disease. ORR (95% CI) was 5.3% (2.7-9.9) in the total and 5.7% (2.4-12.2) in the PD-L1-positive populations. Disease control rate (95% CI) was 7.6% (4.4-12.7) and 9.5% (5.1-16.8), respectively. Median duration of response was not reached in the total (range, 1.2+-21.5+) and in the PD-L1-positive (range, 6.3-21.5+) populations. Median PFS was 2.0 months (95% CI, 1.9-2.0), and the 6-month rate was 14.9%. Median OS was 9.0 months (95% CI, 7.6-11.2), and the 6-month rate was 69.1%. Treatment-related adverse events occurred in 103 (60.6%) patients, including 22 (12.9%) with grade 3 or 4 AEs. There were no deaths due to AEs. CONCLUSIONS Pembrolizumab monotherapy demonstrated durable antitumor activity in a subset of patients with previously treated mTNBC and had a manageable safety profile. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov, NCT02447003.
Collapse
Affiliation(s)
- S Adams
- Department of Medicine, Perlmutter Cancer Center, New York University School of Medicine, New York, USA.
| | - P Schmid
- Centre for Experimental Cancer Medicin, Barts Cancer Institute, Queen Mary University London, London, UK
| | - H S Rugo
- Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco
| | - E P Winer
- Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | | | - A Awada
- Oncology Medicine Departmen, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
| | - D W Cescon
- Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
| | - H Iwata
- Aichi Cancer Center Hospital, Nagoya, Japan
| | - M Campone
- Institut de Cancerologie de l'Ouest, Nantes, France
| | - R Nanda
- Department of Medicin, Section of Hematology/Oncology, The University of Chicago, Chicago, USA
| | - R Hui
- Westmead Hospital and the University of Sydney, Sydney, Australia
| | - G Curigliano
- Department of Oncology and Hematology, University of Milano, Milan; IEO, European Institute of Oncology IRCCS, Milano, Milan, Italy
| | - D Toppmeyer
- Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, USA
| | - J O'Shaughnessy
- Baylor University Medical Center, Dallas; Texas Oncology, Dallas; US Oncology, Dallas, USA
| | - S Loi
- Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - S Paluch-Shimon
- Breast Cancer Service for Young Women, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
| | - A R Tan
- Levine Cancer Institute, Atrium Health, Charlotte
| | - D Card
- Merck & Co., Inc., Kenilworth, USA
| | - J Zhao
- Merck & Co., Inc., Kenilworth, USA
| | | | - J Cortés
- Breast Cancer Program, Vall d'Hebron Institute of Oncology, Barcelona; Ramon y Cajal University Hospital, Madrid; IOB Institute of Oncology, Quiron Group, Barcelona, Spain
| |
Collapse
|
21
|
Paz-Ares L, Spira A, Raben D, Planchard D, Cho BC, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Spigel D, Senan S, Langer CJ, Perez BA, Boothman AM, Broadhurst H, Wadsworth C, Dennis PA, Antonia SJ, Faivre-Finn C. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Ann Oncol 2020; 31:798-806. [PMID: 32209338 DOI: 10.1016/j.annonc.2020.03.287] [Citation(s) in RCA: 122] [Impact Index Per Article: 30.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2020] [Accepted: 03/14/2020] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND In the PACIFIC trial, durvalumab significantly improved progression-free and overall survival (PFS/OS) versus placebo, with manageable safety, in unresectable, stage III non-small-cell lung cancer (NSCLC) patients without progression after chemoradiotherapy (CRT). We report exploratory analyses of outcomes by tumour cell (TC) programmed death-ligand 1 (PD-L1) expression. PATIENTS AND METHODS Patients were randomly assigned (2:1) to intravenous durvalumab 10 mg/kg every 2 weeks or placebo ≤12 months, stratified by age, sex, and smoking history, but not PD-L1 status. Where available, pre-CRT samples were tested for PD-L1 expression (immunohistochemistry) and scored at pre-specified (25%) and post hoc (1%) TC cut-offs. Treatment-effect hazard ratios (HRs) were estimated from unstratified Cox proportional hazards models (Kaplan-Meier-estimated medians). RESULTS In total, 713 patients were randomly assigned, 709 of whom received at least 1 dose of study treatment durvalumab (n = 473) or placebo (n = 236). Some 451 (63%) were PD-L1-assessable: 35%, 65%, 67%, 33%, and 32% had TC ≥25%, <25%, ≥1%, <1%, and 1%-24%, respectively. As of 31 January 2019, median follow-up was 33.3 months. Durvalumab improved PFS versus placebo (primary-analysis data cut-off, 13 February 2017) across all subgroups [HR, 95% confidence interval (CI); medians]: TC ≥25% (0.41, 0.26-0.65; 17.8 versus 3.7 months), <25% (0.59, 0.43-0.82; 16.9 versus 6.9 months), ≥1% (0.46, 0.33-0.64; 17.8 versus 5.6 months), <1% (0.73, 0.48-1.11; 10.7 versus 5.6 months), 1%-24% [0.49, 0.30-0.80; not reached (NR) versus 9.0 months], and unknown (0.59, 0.42-0.83; 14.0 versus 6.4 months). Durvalumab improved OS across most subgroups (31 January 2019 data cut-off; HR, 95% CI; medians): TC ≥ 25% (0.50, 0.30-0.83; NR versus 21.1 months), <25% (0.89, 0.63-1.25; 39.7 versus 37.4 months), ≥1% (0.59, 0.41-0.83; NR versus 29.6 months), 1%-24% (0.67, 0.41-1.10; 43.3 versus 30.5 months), and unknown (0.60, 0.43-0.84; 44.2 versus 23.5 months), but not <1% (1.14, 0.71-1.84; 33.1 versus 45.6 months). Safety was similar across subgroups. CONCLUSIONS PFS benefit with durvalumab was observed across all subgroups, and OS benefit across all but TC <1%, for which limitations and wide HR CI preclude robust conclusions.
Collapse
Affiliation(s)
- L Paz-Ares
- Hospital Universitario 12 de Octubre, Lung Cancer Unit CNIO-H12o, CiberOnc and Universidad Complutense, Madrid, Spain.
| | - A Spira
- Virginia Health Specialists, Fairfax, USA
| | - D Raben
- Department of Radiation Oncology, University of Colorado Denver, Aurora, USA
| | - D Planchard
- Gustave Roussy, Department of Medical Oncology, Thoracic Unit, Villejuif, France
| | - B C Cho
- Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea
| | - M Özgüroğlu
- Istanbul University - Cerrahpaşa, Cerrahpaşa School of Medicine, Istanbul, Turkey
| | - D Daniel
- Tennessee Oncology, Chattanooga and Sarah Cannon Research Institute, Nashville, USA
| | - A Villegas
- Cancer Specialists of North Florida, Jacksonville, USA
| | - D Vicente
- Department of Clinical Oncology, H.U.V. Macarena, Seville, Spain
| | - R Hui
- Westmead Hospital and University of Sydney, Sydney, Australia
| | | | - D Spigel
- Tennessee Oncology, Chattanooga and Sarah Cannon Research Institute, Nashville, USA
| | - S Senan
- Department of Radiation Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands
| | - C J Langer
- Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
| | - B A Perez
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
| | | | | | | | | | - S J Antonia
- H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
| | - C Faivre-Finn
- The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK
| |
Collapse
|
22
|
Gadgeel S, Rodriguez-Abreu D, Felip E, Esteban E, Speranza G, Reck M, Hui R, Boyer M, Garon E, Horinouchi H, Cristescu R, Aurora-Garg D, Lunceford J, Kobie J, Ayers M, Piperdi B, Pietanza M, Garassino M. KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz453.002] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
23
|
Gadgeel S, Garassino M, Esteban E, Speranza G, Felip E, Hochmair M, Powell S, Cheng SS, Bischoff H, Peled N, Hui R, Reck M, Kurata T, Garon E, Boyer M, Yang J, Pietanza M, Rodríguez-Abreu D. O.03 KEYNOTE-189: OS Update and Progression After the Next Line of Therapy (PFS2) with Pembrolizumab + Chemotherapy for Metastatic Nonsquamous NSCLC. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.090] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
24
|
Wu YL, Gray J, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee K, Cho B, Planchard D, Paz-Ares L, Faivre-Finn C, Vansteenkiste J, Spigel D, Taboada M, Dennis P, Özgüroğlu M, Antonia S. Three-year overall survival update from the PACIFIC trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz438.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
Hui R. ES22.05 Role in Thymic Epithelial Tumours. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
26
|
Paz-Ares L, Langer C, Novello S, Halmos B, Cheng Y, Gadgeel S, Hui R, Sugawara S, Borghaei H, Cristescu R, Aurora-Garg D, Albright A, Loboda A, Kobie J, Lunceford J, Ayers M, Lubiniecki G, Pietanza M, Piperdi B, Garassino M. Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.078] [Citation(s) in RCA: 48] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Garassino M, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, Speranza G, Reck M, Hui R, Boyer M, Cristescu R, Aurora-Garg D, Albright A, Loboda A, Kobie J, Lunceford J, Ayers M, Lubiniecki G, Piperdi B, Pietanza M, Garon E. OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.427] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
28
|
Mansfield A, Herbst R, Castro G, Hui R, Peled N, Kim DW, Novello S, Satouchi M, Wu YL, Garon E, Reck M, Robinson A, Samkari A, Piperdi B, Ebiana V, Lin J, Mok T. Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, -010, -024, and -042. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.004] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
Vansteenkiste J, Naidoo J, Faivre-Finn C, Özgüroğlu M, Villegas A, Daniel D, Murakami S, Hui R, Lee K, Cho B, Kubota K, Taboada M, Wadsworth C, Dennis P, Antonia S. Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz259.002] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Reck M, Rodríguez-Abreu D, Robinson A, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Garay T, Jensen E, Ebiana V, Brahmer J. OA14.01 KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.483] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
31
|
Schmid P, Cortés J, Dent R, Pusztai L, McArthur H, Kuemmel S, Bergh J, Denkert C, Park Y, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching P, Cardoso F, Jia L, Karantza V, Zhao J, Aktan G, O’Shaughnessy J. KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.003] [Citation(s) in RCA: 39] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Garassino M, Paz-Ares L, Hui R, Faivre-Finn C, Spira A, Planchard D, Ozguroglu M, Daniel D, Vicente D, Murakami S, Rydén A, Zhang Y, O’Brien C, Dennis P, Antonia S. Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, stage III NSCLC (PACIFIC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz094.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Raben D, Faivre-Finn C, Spigel D, Daniel D, Villegas A, Vincente D, Hui R, de Castro Carpeno J, Murakami S, Paz-Ares L, Özgüroğlu M, Kurata T, Chiappori A, Lee K, de Wit M, Poole L, Wadsworth C, Dennis P, Antonia S. PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.08.057] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
34
|
Kato T, Lee S, Cheng Y, Lee GW, Lee K, Luft A, Trigo J, Hui R, Balint B, Robinson A, Okamoto I, Gerstner G, Paz-Ares L, Li X, Shentu Y, Piperdi B, Tafreshi A. Carboplatin-paclitaxel/nab-paclitaxel with or without pembrolizumab in first-line metastatic squamous NSCLC: Results from the KEYNOTE-407 east Asia subgroup. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy425.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
35
|
Rodriguez Abreu D, Garassino M, Esteban E, Speranza G, Felip E, Domine M, Hochmair M, Powell S, Cheng SS, Bischoff H, Peled N, Hui R, Reck M, Garon E, Boyer M, Grossi F, Jennens R, Yang J, Pietanza M, Gadgeel S. KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes? Ann Oncol 2018. [DOI: 10.1093/annonc/mdy425.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Spigel D, Vansteenkiste J, Reck M, Wakelee H, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Paz-Ares L, Poole L, Wadsworth C, Dennis P, Antonia S. P1.16-05 Effect of Induction Chemotherapy in the PACIFIC Study. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.974] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
37
|
Rodriguez Abreu D, Garassino M, Esteban E, Speranza G, Felip E, Domine M, Hochmair M, Powell S, Cheng SS, Bischoff H, Peled N, Hui R, Reck M, Garon E, Boyer M, Grossi F, Jennens R, Yang J, Pietanza M, Gadgeel S. KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes? Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.086] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Hui R, Pearson A, Cortes Castan J, Campbell C, Poirot C, Azim H, Fumagalli D, Lambertini M, Daly F, Arahmani A, Perez-Garcia J, Aftimos P, Bedard P, Xuereb L, Loibl S, Loi S, Pierrat MJ, Turner N, André F, Curigliano G. Lucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
39
|
Hill J, Nagrial A, Hui R. P3.01-35 Outcomes in Advanced Non-Small Cell Lung Cancer After Discontinuation of PD-1 Checkpoint Inhibitor Due to Toxicity. A Retrospective Study. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1595] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
40
|
Barnet M, Jackson K, Gao B, Nagrial A, Boyer M, Cooper W, Hui R, Linton A, Tattersall M, Russell A, Gibson G, Cebon J, Long G, Menzies A, Scolyer R, Lacaze P, Brink R, Peters T, Cowley M, Gayevskiy V, Thomas D, Pinese M, Blinman P, Kao S, Goodnow C. P1.04-11 Exploring the Germ-Line Contribution to Exceptional Response to PD-1/PD-L1 Inhibition in Patients with NSCLC by Whole Genome Sequencing. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
41
|
Faivre-Finn C, Spigel D, Senan S, Langer C, Raben D, Perez B, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Paz-Ares L, Poole L, Wadsworth C, Dennis P, Antonia S. Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy291] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee K, De Wit M, Cho B, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim Y, Karapetis C, Hiret S, Ostoros G, Kubota K, Gray J, Paz-Ares L, De Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel D, Wadsworth C, Taboada M, Dennis P, Özgüroğlu M. PL02.01 Overall Survival with Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
43
|
Socinski M, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Gray J, Park K, Vincent M, Perrone F, Poole L, Wadsworth C, Dennis P, Antonia S. P1.16-04 Outcomes of Patients <70 or ≥70 Years of Age in PACIFIC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.973] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
44
|
Riely G, Hui R, Carbone D, Park K, Carrigan M, Xu X, Dang T, Chih-Hsin Yang J. P1.01-81 Phase 3 Study of Pemetrexed-Platinum with or without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.637] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
45
|
Garassino M, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, Speranza G, Domine M, Hochmair M, Powell S, Cheng S, Bischoff H, Peled N, Reck M, Hui R, Garon E, Boyer M, Yang J, Burke T, Pietanza M, Gandhi L. PD.1.01 Health-Related Quality of Life with Pembrolizumab or Placebo + Pemetrexed + Platinum in Non-Squamous NSCLC: KEYNOTE-189. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.07.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
46
|
Zhang S, Tao L, Hui R, Zhang W. P3805Evaluation of blood pressure lowering effect by generic and brand-name antihypertensive drug treatment: a prospective multicenter study in China. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- S Zhang
- Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, State Key Laboratory of Cardiovascular Disease, Beijing, China People's Republic of
| | - L Tao
- Peking University Third Hospital, Research Center of Clinical Epidemiology, Beijing, China People's Republic of
| | - R Hui
- Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, State Key Laboratory of Cardiovascular Disease, Beijing, China People's Republic of
| | - W Zhang
- Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, State Key Laboratory of Cardiovascular Disease, Beijing, China People's Republic of
| |
Collapse
|
47
|
Dhillon HM, Bell ML, van der Ploeg HP, Turner JD, Kabourakis M, Spencer L, Lewis C, Hui R, Blinman P, Clarke SJ, Boyer MJ, Vardy JL. Impact of physical activity on fatigue and quality of life in people with advanced lung cancer: a randomized controlled trial. Ann Oncol 2018; 28:1889-1897. [PMID: 28459989 DOI: 10.1093/annonc/mdx205] [Citation(s) in RCA: 67] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
Background Physical activity (PA) improves fatigue and quality of life (QOL) in cancer survivors. Our aim was to assess whether a 2-month PA intervention improves fatigue and QOL for people with advanced lung cancer. Methods Participants with advanced lung cancer, Eastern Cooperative Oncology Group performance status (PS) ≤2, >6 months life expectancy, and ability to complete six-min walk test, were stratified (disease stage, PS 0-1 versus 2, centre) and randomized (1:1) in an open-label study to usual care (UC) (nutrition and PA education materials) or experimental intervention (EX): UC plus 2-month supervised weekly PA and behaviour change sessions. Assessments occurred at baseline, 2, 4, and 6 months. The primary endpoint was fatigue [Functional Assessment of Cancer Therapy-Fatigue (FACT-F) questionnaire] at 2 months. The study was designed to detect a difference in mean FACT-F subscale score of 6. Analysis was intention-to-treat using linear mixed models. Results We recruited 112 patients: 56 (50.4%) were randomized to EX, 55(49.5%) to UC; 1 ineligible. Male 55%; median age 64 years (34-80); 106 (96%) non-small cell lung cancer; 106 (95.5%) stage IV. At 2, 4 and 6 months, 90, 73 and 62 participants were assessed, respectively, with no difference in attrition between groups. There were no significant differences in fatigue between the groups at 2, 4 or 6 months: mean scores at 2 months EX 37.5, UC 36.4 (difference 1.2, 95% CI - 3.5, 5.8, P = 0.62). There were no significant differences in QOL, symptoms, physical or functional status, or survival. Conclusions Adherence to the intervention was good but the intervention group did not increase their PA enough compared to the control group, and no difference was seen in fatigue or QOL. Trial Registration Australian New Zealand Clinical Trials Registry No. ACTRN12609000971235.
Collapse
Affiliation(s)
- H M Dhillon
- Centre for Medical Psychology and Evidence-Based Decision-Making, University of Sydney, Sydney, Australia
| | - M L Bell
- Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, USA
| | - H P van der Ploeg
- Department of Public and Occupational Health and EMGO Institute for Health and Care Research, VU University Medical Center Amsterdam, Amsterdam, The Netherlands
| | - J D Turner
- Centre for Medical Psychology and Evidence-Based Decision-Making, University of Sydney, Sydney, Australia
| | - M Kabourakis
- Centre for Medical Psychology and Evidence-Based Decision-Making, University of Sydney, Sydney, Australia
| | - L Spencer
- Physiotherapy Department, Royal Prince Alfred Hospital, Camperdown
| | - C Lewis
- Medical Oncology Department, Prince of Wales Hospital, Randwick
| | - R Hui
- Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead
| | - P Blinman
- Concord Cancer Centre, Concord Repatriation General Hospital, Concord
| | - S J Clarke
- Sydney Medical School, University of Sydney, Sydney
| | - M J Boyer
- Medical Oncology Department, Chris O'Brien Lifehouse, Camperdown, Australia
| | - J L Vardy
- Centre for Medical Psychology and Evidence-Based Decision-Making, University of Sydney, Sydney, Australia.,Concord Cancer Centre, Concord Repatriation General Hospital, Concord.,Sydney Medical School, University of Sydney, Sydney
| |
Collapse
|
48
|
Garassino M, Rubin S, Zhao Y, Luo Y, Samkari A, Hui R. 193TiP Phase 3 study of epacadostat plus pembrolizumab with or without platinum-based chemotherapy vs pembrolizumab plus chemotherapy for first-line metastatic non-small cell lung cancer (mNSCLC): ECHO-306/KEYNOTE-715. J Thorac Oncol 2018. [DOI: 10.1016/s1556-0864(18)30466-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
49
|
Hui R, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Rydén A, Zhang Y, Dennis P, Antonia S. 233O Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: Post-hoc analysis of PACIFIC patient-reported outcomes. J Thorac Oncol 2018. [DOI: 10.1016/s1556-0864(18)30401-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
50
|
Ejlertsen B, Chan A, Gnant M, von Minckwitz G, Delaloge S, Buyse M, O'Shaughnessy J, Mansi J, Moy B, Iwata H, Wong A, Ye Y, Means-Powell J, Hui R, Ruiz-Borrego M, Ruiz Simon A, Shen ZZ, Holmes FA, Lesniewski-Kmak K, Martin M. Abstract P1-13-05: Timing of initiation of neratinib after completion of trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: Exploratory analyses from the phase III ExteNET trial. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p1-13-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The international, randomized, placebo-controlled phase III ExteNET trial showed that 1 year of neratinib after trastuzumab-based adjuvant therapy significantly improved 2-year invasive disease-free survival (iDFS) in early-stage HER2+ breast cancer (HR 0.67; 95% CI 0.50–0.91; p=0.009) [Chan et al. Lancet Oncol 2016]. The significant iDFS benefit with neratinib was maintained after a median of 5 years' follow-up (HR 0.73; 95% CI 0.57-0.92; p=0.008) [Martin et al. ESMO 2017]. We present exploratory analyses from the ExteNET trial examining the effects of the interval between completion of trastuzumab and randomization to commence neratinib on iDFS.
Methods: Women with early-stage HER2+ breast cancer were randomly assigned to oral neratinib 240 mg/day or placebo for 1 year after standard primary therapy and trastuzumab-based adjuvant therapy. Under the original study protocol, (neo)adjuvant trastuzumab was to be completed ≤24 months before randomization; this was revised to ≤12 months before randomization after the NCCTG-N9831/NSABP B-31 4-year analysis showed that the risk of relapse is greatest during the first 12 months after completing trastuzumab. Disease recurrences were collected prospectively during 1 and 2 years post-randomization, and from medical records during 3–5 years post-randomization. Patients randomized ≤12 months after completion of adjuvant trastuzumab were further separated to look at those who initiated neratinib ≤6 months of completing adjuvant trastuzumab. Primary endpoint: iDFS. HR (95% CI) estimated using Cox proportional-hazards models. Data cut-off: March 1, 2017. Clinicaltrials.gov: NCT00878709.
Results:The intention-to-treat population comprised 2840 patients (neratinib, n=1420; placebo, n=1420). Median time from last trastuzumab dose to randomization was 4.4 and 4.6 months in the neratinib and placebo groups, respectively. 81% of patients were randomized ≤12 months of completing trastuzumab. The effects of the interval between the last dose of trastuzumab and randomization/initiation of neratinib on iDFS after a median follow-up of 5.2 years are shown in the table.
Estimated 5-year iDFS rate, % P-valueInterval from last dose of trastuzumab to randomizationnNeratinibPlaceboHR (95% CI)a(2-sided)≤6 months164190.085.40.62 (0.46–0.84)0.002≤12 monthsb229789.786.50.70 (0.54–0.90)0.006>12 monthsb54392.392.61.00 (0.51–1.94)0.992a. Neratinib vs placebo; b. Protocol-defined subgroups
Conclusions: In ExteNET, patients who initiated neratinib within 12 months of completing trastuzumab-based adjuvant therapy appeared to derive greater benefit from treatment than those who started neratinib later. Further, exploratory analyses suggest that the magnitude of benefit with neratinib is greater if initiated sooner (i.e. within 6 months of completing trastuzumab). Given the benefits of neratinib overall in those initiating treatment ≤12 months from the end of adjuvant trastuzumab, extended adjuvant treatment with neratinib should be initiated early following completion of trastuzumab.
Citation Format: Ejlertsen B, Chan A, Gnant M, von Minckwitz G, Delaloge S, Buyse M, O'Shaughnessy J, Mansi J, Moy B, Iwata H, Wong A, Ye Y, Means-Powell J, Hui R, Ruiz-Borrego M, Ruiz Simon A, Shen Z-Z, Holmes FA, Lesniewski-Kmak K, Martin M. Timing of initiation of neratinib after completion of trastuzumab-based adjuvant therapy in early-stage HER2+ breast cancer: Exploratory analyses from the phase III ExteNET trial [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-13-05.
Collapse
Affiliation(s)
- B Ejlertsen
- Rigshospitalet, Copenhagen, Denmark; Breast Cancer Research Centre-Western Australia and Curtin University; Comprehensive Cancer Centre, Medical University of Vienna; German Breast Group; Institut Gustave Roussy; International Drug Development Institute; Texas Oncology-Baylor Charles A. Sammons Cancer Center; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London; Massachusetts General Hospital Cancer Center; Aichi Cancer Center Hospital; Puma Biotechnology Inc; Vanderbilt-Ingram Cancer Center; Westmead Hospital and the University of Sydney, Sydney, NSW, Australia; Hospital Universitario Virgen del Rocio; Instituto Valenciano de Oncología; Shanghai Cancer Center; Texas Oncology; Szpital Morski im. PCK Oddiział Onkologii Klinicznej, Gdyńskie Centrum Onkologii; Hospital General Universitario Gregorio Marañón
| | - A Chan
- Rigshospitalet, Copenhagen, Denmark; Breast Cancer Research Centre-Western Australia and Curtin University; Comprehensive Cancer Centre, Medical University of Vienna; German Breast Group; Institut Gustave Roussy; International Drug Development Institute; Texas Oncology-Baylor Charles A. Sammons Cancer Center; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London; Massachusetts General Hospital Cancer Center; Aichi Cancer Center Hospital; Puma Biotechnology Inc; Vanderbilt-Ingram Cancer Center; Westmead Hospital and the University of Sydney, Sydney, NSW, Australia; Hospital Universitario Virgen del Rocio; Instituto Valenciano de Oncología; Shanghai Cancer Center; Texas Oncology; Szpital Morski im. PCK Oddiział Onkologii Klinicznej, Gdyńskie Centrum Onkologii; Hospital General Universitario Gregorio Marañón
| | - M Gnant
- Rigshospitalet, Copenhagen, Denmark; Breast Cancer Research Centre-Western Australia and Curtin University; Comprehensive Cancer Centre, Medical University of Vienna; German Breast Group; Institut Gustave Roussy; International Drug Development Institute; Texas Oncology-Baylor Charles A. Sammons Cancer Center; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London; Massachusetts General Hospital Cancer Center; Aichi Cancer Center Hospital; Puma Biotechnology Inc; Vanderbilt-Ingram Cancer Center; Westmead Hospital and the University of Sydney, Sydney, NSW, Australia; Hospital Universitario Virgen del Rocio; Instituto Valenciano de Oncología; Shanghai Cancer Center; Texas Oncology; Szpital Morski im. PCK Oddiział Onkologii Klinicznej, Gdyńskie Centrum Onkologii; Hospital General Universitario Gregorio Marañón
| | - G von Minckwitz
- Rigshospitalet, Copenhagen, Denmark; Breast Cancer Research Centre-Western Australia and Curtin University; Comprehensive Cancer Centre, Medical University of Vienna; German Breast Group; Institut Gustave Roussy; International Drug Development Institute; Texas Oncology-Baylor Charles A. Sammons Cancer Center; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London; Massachusetts General Hospital Cancer Center; Aichi Cancer Center Hospital; Puma Biotechnology Inc; Vanderbilt-Ingram Cancer Center; Westmead Hospital and the University of Sydney, Sydney, NSW, Australia; Hospital Universitario Virgen del Rocio; Instituto Valenciano de Oncología; Shanghai Cancer Center; Texas Oncology; Szpital Morski im. PCK Oddiział Onkologii Klinicznej, Gdyńskie Centrum Onkologii; Hospital General Universitario Gregorio Marañón
| | - S Delaloge
- Rigshospitalet, Copenhagen, Denmark; Breast Cancer Research Centre-Western Australia and Curtin University; Comprehensive Cancer Centre, Medical University of Vienna; German Breast Group; Institut Gustave Roussy; International Drug Development Institute; Texas Oncology-Baylor Charles A. Sammons Cancer Center; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London; Massachusetts General Hospital Cancer Center; Aichi Cancer Center Hospital; Puma Biotechnology Inc; Vanderbilt-Ingram Cancer Center; Westmead Hospital and the University of Sydney, Sydney, NSW, Australia; Hospital Universitario Virgen del Rocio; Instituto Valenciano de Oncología; Shanghai Cancer Center; Texas Oncology; Szpital Morski im. PCK Oddiział Onkologii Klinicznej, Gdyńskie Centrum Onkologii; Hospital General Universitario Gregorio Marañón
| | - M Buyse
- Rigshospitalet, Copenhagen, Denmark; Breast Cancer Research Centre-Western Australia and Curtin University; Comprehensive Cancer Centre, Medical University of Vienna; German Breast Group; Institut Gustave Roussy; International Drug Development Institute; Texas Oncology-Baylor Charles A. Sammons Cancer Center; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London; Massachusetts General Hospital Cancer Center; Aichi Cancer Center Hospital; Puma Biotechnology Inc; Vanderbilt-Ingram Cancer Center; Westmead Hospital and the University of Sydney, Sydney, NSW, Australia; Hospital Universitario Virgen del Rocio; Instituto Valenciano de Oncología; Shanghai Cancer Center; Texas Oncology; Szpital Morski im. PCK Oddiział Onkologii Klinicznej, Gdyńskie Centrum Onkologii; Hospital General Universitario Gregorio Marañón
| | - J O'Shaughnessy
- Rigshospitalet, Copenhagen, Denmark; Breast Cancer Research Centre-Western Australia and Curtin University; Comprehensive Cancer Centre, Medical University of Vienna; German Breast Group; Institut Gustave Roussy; International Drug Development Institute; Texas Oncology-Baylor Charles A. Sammons Cancer Center; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London; Massachusetts General Hospital Cancer Center; Aichi Cancer Center Hospital; Puma Biotechnology Inc; Vanderbilt-Ingram Cancer Center; Westmead Hospital and the University of Sydney, Sydney, NSW, Australia; Hospital Universitario Virgen del Rocio; Instituto Valenciano de Oncología; Shanghai Cancer Center; Texas Oncology; Szpital Morski im. PCK Oddiział Onkologii Klinicznej, Gdyńskie Centrum Onkologii; Hospital General Universitario Gregorio Marañón
| | - J Mansi
- Rigshospitalet, Copenhagen, Denmark; Breast Cancer Research Centre-Western Australia and Curtin University; Comprehensive Cancer Centre, Medical University of Vienna; German Breast Group; Institut Gustave Roussy; International Drug Development Institute; Texas Oncology-Baylor Charles A. Sammons Cancer Center; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London; Massachusetts General Hospital Cancer Center; Aichi Cancer Center Hospital; Puma Biotechnology Inc; Vanderbilt-Ingram Cancer Center; Westmead Hospital and the University of Sydney, Sydney, NSW, Australia; Hospital Universitario Virgen del Rocio; Instituto Valenciano de Oncología; Shanghai Cancer Center; Texas Oncology; Szpital Morski im. PCK Oddiział Onkologii Klinicznej, Gdyńskie Centrum Onkologii; Hospital General Universitario Gregorio Marañón
| | - B Moy
- Rigshospitalet, Copenhagen, Denmark; Breast Cancer Research Centre-Western Australia and Curtin University; Comprehensive Cancer Centre, Medical University of Vienna; German Breast Group; Institut Gustave Roussy; International Drug Development Institute; Texas Oncology-Baylor Charles A. Sammons Cancer Center; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London; Massachusetts General Hospital Cancer Center; Aichi Cancer Center Hospital; Puma Biotechnology Inc; Vanderbilt-Ingram Cancer Center; Westmead Hospital and the University of Sydney, Sydney, NSW, Australia; Hospital Universitario Virgen del Rocio; Instituto Valenciano de Oncología; Shanghai Cancer Center; Texas Oncology; Szpital Morski im. PCK Oddiział Onkologii Klinicznej, Gdyńskie Centrum Onkologii; Hospital General Universitario Gregorio Marañón
| | - H Iwata
- Rigshospitalet, Copenhagen, Denmark; Breast Cancer Research Centre-Western Australia and Curtin University; Comprehensive Cancer Centre, Medical University of Vienna; German Breast Group; Institut Gustave Roussy; International Drug Development Institute; Texas Oncology-Baylor Charles A. Sammons Cancer Center; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London; Massachusetts General Hospital Cancer Center; Aichi Cancer Center Hospital; Puma Biotechnology Inc; Vanderbilt-Ingram Cancer Center; Westmead Hospital and the University of Sydney, Sydney, NSW, Australia; Hospital Universitario Virgen del Rocio; Instituto Valenciano de Oncología; Shanghai Cancer Center; Texas Oncology; Szpital Morski im. PCK Oddiział Onkologii Klinicznej, Gdyńskie Centrum Onkologii; Hospital General Universitario Gregorio Marañón
| | - A Wong
- Rigshospitalet, Copenhagen, Denmark; Breast Cancer Research Centre-Western Australia and Curtin University; Comprehensive Cancer Centre, Medical University of Vienna; German Breast Group; Institut Gustave Roussy; International Drug Development Institute; Texas Oncology-Baylor Charles A. Sammons Cancer Center; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London; Massachusetts General Hospital Cancer Center; Aichi Cancer Center Hospital; Puma Biotechnology Inc; Vanderbilt-Ingram Cancer Center; Westmead Hospital and the University of Sydney, Sydney, NSW, Australia; Hospital Universitario Virgen del Rocio; Instituto Valenciano de Oncología; Shanghai Cancer Center; Texas Oncology; Szpital Morski im. PCK Oddiział Onkologii Klinicznej, Gdyńskie Centrum Onkologii; Hospital General Universitario Gregorio Marañón
| | - Y Ye
- Rigshospitalet, Copenhagen, Denmark; Breast Cancer Research Centre-Western Australia and Curtin University; Comprehensive Cancer Centre, Medical University of Vienna; German Breast Group; Institut Gustave Roussy; International Drug Development Institute; Texas Oncology-Baylor Charles A. Sammons Cancer Center; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London; Massachusetts General Hospital Cancer Center; Aichi Cancer Center Hospital; Puma Biotechnology Inc; Vanderbilt-Ingram Cancer Center; Westmead Hospital and the University of Sydney, Sydney, NSW, Australia; Hospital Universitario Virgen del Rocio; Instituto Valenciano de Oncología; Shanghai Cancer Center; Texas Oncology; Szpital Morski im. PCK Oddiział Onkologii Klinicznej, Gdyńskie Centrum Onkologii; Hospital General Universitario Gregorio Marañón
| | - J Means-Powell
- Rigshospitalet, Copenhagen, Denmark; Breast Cancer Research Centre-Western Australia and Curtin University; Comprehensive Cancer Centre, Medical University of Vienna; German Breast Group; Institut Gustave Roussy; International Drug Development Institute; Texas Oncology-Baylor Charles A. Sammons Cancer Center; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London; Massachusetts General Hospital Cancer Center; Aichi Cancer Center Hospital; Puma Biotechnology Inc; Vanderbilt-Ingram Cancer Center; Westmead Hospital and the University of Sydney, Sydney, NSW, Australia; Hospital Universitario Virgen del Rocio; Instituto Valenciano de Oncología; Shanghai Cancer Center; Texas Oncology; Szpital Morski im. PCK Oddiział Onkologii Klinicznej, Gdyńskie Centrum Onkologii; Hospital General Universitario Gregorio Marañón
| | - R Hui
- Rigshospitalet, Copenhagen, Denmark; Breast Cancer Research Centre-Western Australia and Curtin University; Comprehensive Cancer Centre, Medical University of Vienna; German Breast Group; Institut Gustave Roussy; International Drug Development Institute; Texas Oncology-Baylor Charles A. Sammons Cancer Center; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London; Massachusetts General Hospital Cancer Center; Aichi Cancer Center Hospital; Puma Biotechnology Inc; Vanderbilt-Ingram Cancer Center; Westmead Hospital and the University of Sydney, Sydney, NSW, Australia; Hospital Universitario Virgen del Rocio; Instituto Valenciano de Oncología; Shanghai Cancer Center; Texas Oncology; Szpital Morski im. PCK Oddiział Onkologii Klinicznej, Gdyńskie Centrum Onkologii; Hospital General Universitario Gregorio Marañón
| | - M Ruiz-Borrego
- Rigshospitalet, Copenhagen, Denmark; Breast Cancer Research Centre-Western Australia and Curtin University; Comprehensive Cancer Centre, Medical University of Vienna; German Breast Group; Institut Gustave Roussy; International Drug Development Institute; Texas Oncology-Baylor Charles A. Sammons Cancer Center; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London; Massachusetts General Hospital Cancer Center; Aichi Cancer Center Hospital; Puma Biotechnology Inc; Vanderbilt-Ingram Cancer Center; Westmead Hospital and the University of Sydney, Sydney, NSW, Australia; Hospital Universitario Virgen del Rocio; Instituto Valenciano de Oncología; Shanghai Cancer Center; Texas Oncology; Szpital Morski im. PCK Oddiział Onkologii Klinicznej, Gdyńskie Centrum Onkologii; Hospital General Universitario Gregorio Marañón
| | - A Ruiz Simon
- Rigshospitalet, Copenhagen, Denmark; Breast Cancer Research Centre-Western Australia and Curtin University; Comprehensive Cancer Centre, Medical University of Vienna; German Breast Group; Institut Gustave Roussy; International Drug Development Institute; Texas Oncology-Baylor Charles A. Sammons Cancer Center; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London; Massachusetts General Hospital Cancer Center; Aichi Cancer Center Hospital; Puma Biotechnology Inc; Vanderbilt-Ingram Cancer Center; Westmead Hospital and the University of Sydney, Sydney, NSW, Australia; Hospital Universitario Virgen del Rocio; Instituto Valenciano de Oncología; Shanghai Cancer Center; Texas Oncology; Szpital Morski im. PCK Oddiział Onkologii Klinicznej, Gdyńskie Centrum Onkologii; Hospital General Universitario Gregorio Marañón
| | - Z-Z Shen
- Rigshospitalet, Copenhagen, Denmark; Breast Cancer Research Centre-Western Australia and Curtin University; Comprehensive Cancer Centre, Medical University of Vienna; German Breast Group; Institut Gustave Roussy; International Drug Development Institute; Texas Oncology-Baylor Charles A. Sammons Cancer Center; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London; Massachusetts General Hospital Cancer Center; Aichi Cancer Center Hospital; Puma Biotechnology Inc; Vanderbilt-Ingram Cancer Center; Westmead Hospital and the University of Sydney, Sydney, NSW, Australia; Hospital Universitario Virgen del Rocio; Instituto Valenciano de Oncología; Shanghai Cancer Center; Texas Oncology; Szpital Morski im. PCK Oddiział Onkologii Klinicznej, Gdyńskie Centrum Onkologii; Hospital General Universitario Gregorio Marañón
| | - FA Holmes
- Rigshospitalet, Copenhagen, Denmark; Breast Cancer Research Centre-Western Australia and Curtin University; Comprehensive Cancer Centre, Medical University of Vienna; German Breast Group; Institut Gustave Roussy; International Drug Development Institute; Texas Oncology-Baylor Charles A. Sammons Cancer Center; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London; Massachusetts General Hospital Cancer Center; Aichi Cancer Center Hospital; Puma Biotechnology Inc; Vanderbilt-Ingram Cancer Center; Westmead Hospital and the University of Sydney, Sydney, NSW, Australia; Hospital Universitario Virgen del Rocio; Instituto Valenciano de Oncología; Shanghai Cancer Center; Texas Oncology; Szpital Morski im. PCK Oddiział Onkologii Klinicznej, Gdyńskie Centrum Onkologii; Hospital General Universitario Gregorio Marañón
| | - K Lesniewski-Kmak
- Rigshospitalet, Copenhagen, Denmark; Breast Cancer Research Centre-Western Australia and Curtin University; Comprehensive Cancer Centre, Medical University of Vienna; German Breast Group; Institut Gustave Roussy; International Drug Development Institute; Texas Oncology-Baylor Charles A. Sammons Cancer Center; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London; Massachusetts General Hospital Cancer Center; Aichi Cancer Center Hospital; Puma Biotechnology Inc; Vanderbilt-Ingram Cancer Center; Westmead Hospital and the University of Sydney, Sydney, NSW, Australia; Hospital Universitario Virgen del Rocio; Instituto Valenciano de Oncología; Shanghai Cancer Center; Texas Oncology; Szpital Morski im. PCK Oddiział Onkologii Klinicznej, Gdyńskie Centrum Onkologii; Hospital General Universitario Gregorio Marañón
| | - M Martin
- Rigshospitalet, Copenhagen, Denmark; Breast Cancer Research Centre-Western Australia and Curtin University; Comprehensive Cancer Centre, Medical University of Vienna; German Breast Group; Institut Gustave Roussy; International Drug Development Institute; Texas Oncology-Baylor Charles A. Sammons Cancer Center; Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London; Massachusetts General Hospital Cancer Center; Aichi Cancer Center Hospital; Puma Biotechnology Inc; Vanderbilt-Ingram Cancer Center; Westmead Hospital and the University of Sydney, Sydney, NSW, Australia; Hospital Universitario Virgen del Rocio; Instituto Valenciano de Oncología; Shanghai Cancer Center; Texas Oncology; Szpital Morski im. PCK Oddiział Onkologii Klinicznej, Gdyńskie Centrum Onkologii; Hospital General Universitario Gregorio Marañón
| |
Collapse
|